Acute Myeloid Leukemia


Venclexta® and Low-doses of Cytarabine Effective in Elderly with Acute Myeloid Leukemia (January 26, 2017)

The treatment combination consisting of Venclexta® (venetoclax) plus low-doses of the chemotherapy agent cytarabine appears to be an effective and tolerable treatment regimen for elderly patients with... Continue Reading

FDA Priority Review Granted for Midostaurin in Leukemia (November 17, 2016)

The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well... Continue Reading

LLS Launches Groundbreaking Precision Medicine Approach To Treat AML (November 1, 2016)

Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) announced the launch of a groundbreaking, collaborative clinical trial for acute... Continue Reading

Pass It On: July is National Leukemia and Lymphoma Awareness Month (September 1, 2016)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia... Continue Reading

Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia (August 9, 2016)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational drug Pracinostat in combination with azacitidine for the treatment of elderly patients with... Continue Reading

GlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia (July 4, 2016)

GlycoMimetics, Inc. has announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-selectin antagonist GMI-1271 for treatment of adult patients with... Continue Reading

About PCROWD, Dana-Farber’s tissue-banking study for patients with Myeloproliferative Neoplasms, Smoldering Multiple Myeloma, Smoldering Waldenstrom’s Macroglobulemia, and Early Myelodysplastic Syndromes (June 27, 2016)

PCROWD (“Precursor CROWDsourcing”) – a tissue banking and clinical information study and repository – is an indispensable component of the blood cancer research pipeline. The main objective... Continue Reading

Vyxeos™ Improves Survival for Elderly in AML (March 30, 2016)

Results from a recent phase III clinical trial have demonstrated an improved survival benefit with the use of Vyxeos (CPX-351) compared with the standard chemotherapy combination consisting of cytarabine... Continue Reading

Midostaurin Receives Breakthough Therapy Designation for Acute Myeloid Leukemia (March 16, 2016)

The targeted agent midostaurin (PKC412), which is still in investigative stages, has received “breakthrough therapy” designation by the United States Food and Drug Administration (FDA) for the treatment... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented... Continue Reading

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant (December 30, 2015)

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

Promising Survival for AML Patients Treated with Stem Cells from Related Half Matched Donor (July 30, 2015)

Patients with acute myeloid leukemia (AML) may have a promising new treatment option. Research shows that stem cell transplant from a “half matched” related donor plus chemotherapy results in similar... Continue Reading

CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients (January 28, 2015)

The U. S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigational drug CPX-351, a liposomal formulation of cytarabine-daunorubicin, for the treatment of elderly patients... Continue Reading

Actinium Receives Orphan-drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients (December 8, 2014)

Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the US Food and Drug Administration... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (August 8, 2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now... Continue Reading

Mylotarg Reduces Risk of Relapse in Childhood AML (December 20, 2013)

Mylotarg® (gemtuzumab ozogamicin)—a drug that was withdrawn from the market in 2010 because of uncertain benefit and safety concerns—reduces the risk of relapse in children and young adults with acute... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS